Low-Dose Dimethyl Sulfoxide Suppresses Androgen Receptor and Its Splice Variant AR-V7 in Castration-Resistant Prostate Cancer Cells
August 2025
in “
Therapeutics
”
TLDR Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.
The study demonstrates that low-dose dimethyl sulfoxide (DMSO) effectively suppresses androgen receptor (AR) and its splice variant AR-V7 in castration-resistant prostate cancer (CRPC) cells, specifically in 22Rv1 and C4-2B cell lines. DMSO showed a dose-dependent inhibitory effect on AR expression, with significant suppression of AR-V7 at concentrations as low as 0.5% and AR-FL at 2.5%. Additionally, DMSO reduced cell migration and exhibited antiproliferative and antimetastatic effects without significant cytotoxicity. The findings suggest that low-dose DMSO could be a safe and effective treatment option for CRPC, potentially enhancing the efficacy of conventional therapies.